Your trusted guide to clinical trials
Find clinical trials relevant to you, near you. Powered by AI.
Browse Trials by Condition
- Neoplasms 18,336
- Lymphocytic Leukemia, Acute 15,317
- Muscular Dystrophy 15,154
- Metastatic Cancer 10,936
- Neoplasm Metastasis 10,819
- Menstruation 8,794
- Surgery 8,770
- Carcinoma 6,658
- Uterine Fibroids 6,571
- Neurologic Disorders 6,499
- Pain 5,897
- Chemotherapy 5,309
- Wounds 4,979
- Lung Disease 4,726
- Allergy 4,144
- Vascular Diseases 3,926
- Vision Loss 3,750
- Heart Disease 3,222
- Cardiac Disease 3,207
- Depression 3,050
- Inflammation 2,894
TrialX — your clinical trial finder
A new, easy way to participate in clinical studies.
You are in great company.
Institutes that trust us.
New & updated studies
Browse all studies
Benefit of Adding Cureety TechCare Telemonitoring to Usual Care During Injectable Anticancer Treatment
Currently, during usual care, it is critical to assess whether a patient is apt to receive injectable anticancer treatment in the days prior to the administration. To assess this, blood tests are usually performed in the days leading up to the planned administration. A hospital staff member then telephones the …
Intraoral Scanners as Periodontal and Dental Pathologies Diagnosis Tools
Periodontal diseases and dental pathologies are highly prevalent oral diseases. Thirty-three to fifty percent of adult population presented at least one untreated caries and more than 50% of French population are affected by severe periodontitis. These diseases affect dental organ or periodontal attached system but could have negative impact on …
Clinical Characteristics and Temporal Properties of Individual Tics in Persistent Tic Disorder
The goal of this clinical study is to learn more about the timing of tics (sudden, fast movements and sounds that people do and make without meaning to) in people who have multiple tics that have been going on for more than one year. The main questions it aims to …
Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are human genes that produce tumor suppressor …
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The primary hypotheses are that (1) nemtabrutinib is non-inferior to ibrutinib or acalabrutinib with respect to …
A Study of Implantation of CRENEOUS ENTERPRISE 2 Intracranial Stent in Participants With Severe Symptomatic Intracranial Atherosclerotic Stenosis
The purpose of this study is to evaluate the safety and effectiveness of CERENOVUS ENTERPRISE 2 intracranial stent implantation in treatment of participants with severe symptomatic intracranial atherosclerotic stenosis.
Your clinical trial journey
Find a study
Search or browse for a clinical trial near you.
Check Eligibility
Learn more about the trial and check to see if you are eligible to take part in it.
Participate
If you prequalify, connect with the study team and let your trial journey begin!
Accelerating clinical research powered by AI
Building patient connection for a better future
Join us in our mission to help accelerate clinical research.
We are on a mission to make 1 billion actions made towards clinical research. ‘Actions’ are anything from searching for trials, sharing a trial, getting in touch with a study team — or something as simple as becoming a volunteer.